Presentatie - vzw farmaka asbl

More documents

Recommendations

Info

Sartanen Gami P. Secondary prevention of ischaemic cardiac events. Clinical Evidence 2007. Design N/n Population Sd Interventions Outcomes Results RCT n=40 6 previous coronary revascularisation, most of whom were not taking ACE inhibitors 2y -Candesartan 4 mg + usual care -Usual care alone Combined cardiovascular endpoint (revascularisation, nonfatal MI, cardiovascular death) ONTARGET investigators. NEJM 2008;358:1547-59 Design N/n Population Sd Interventions Outcomes Results RCT, double blind n=25 620 56m -Ramipril -Telmisartan -Combination - Vascular disease (coronary (history of MI, stable angina and others), peripheral or stroke) or high-risk diabetes with endorgan damage - +/-35% stable angina - 68% hypertension - Mean base blood pressure: 141,8 / 82,1 mmHg - Behandeling: anti-aggregans, ß- blokker, diureticum en/ of hypolipemiërend middel - Exclusie: klinisch hartfalen Primary composite outcome (death from cv causes, MI, stroke or hospitalisation for heart failure) Cough Angio-edema Hypotensive symptoms Syncope Renal dysfunction 5.9% (candesartan) vs 12.3%; p=0.03 RR=0.47 (95%CI 0.24 to 0.93) 16.5% (ramipril) vs 16.7% (telmisartan) vs 16.3% (combination) RR (rami vs telmi) =1.01 (95%CI 0.94 to 1.09) Telmisartan “niet minder doeltreffend” (non-inferiority trial) RR (combi vs rami)= 0.99 (95%CI 0.92 to 1.07) Combinatie niet doeltreffender 1.1 (telmi) vs 4.2% (rami); p
- Sartanen - • Ramipril vs telmisartan – ONTARGET studie – Telmisartan even werkzaam als ramipril bij cardiovasculaire hoogrisicopopulatie – Minder hoest (NNT 33) en angio-oedeem (NNT 500) met telmisartan ONTARGET NEJM 2008 www.<strong>farmaka</strong>.be Project Farmaka
Page 1 and 2:
Projekt Farmaka vzw Centrum voor on
Page 3 and 4:
Hoe? 1. Van een klinisch probleem n
Page 5 and 6:
Aanpak van stabiele angor www.farma
Page 7 and 8:
Definitie en epidemiologie www.farm
Page 9 and 10:
Natuurlijk verloop www.farmaka.be P
Page 11 and 12:
Doelstelling van de behandeling www
Page 13 and 14:
Acute behandeling www.farmaka.be Pr
Page 15 and 16:
Anti-anginosa (onderhoudsbehandelin
Page 17 and 18:
ANTIANGINOSA (niet in België) - we
Page 19 and 20:
β-blokkers Niet-selectieve β-blok
Page 21:
NITRATEN Sublinguaal Posologie Isos
Page 24 and 25:
β-blokkers 17.Pepine. The atenolol
Page 26 and 27:
β-blokkers Preserved ventricular f
Page 28 and 29:
β-blokkers Helfand 2007 www.farmak
Page 30 and 31:
- β-blokkers - • Mortaliteit en
Page 32 and 33:
Calcium-antagonisten Gami P. Second
Page 34 and 35:
• Werkzaam op angor - Calciumanta
Page 36 and 37:
Nitraten 25.Heidenreich. JAMA 1999;
Page 38 and 39:
- Molsidomine - • Werkzaamheid op
Page 40 and 41: - Trimetazidine, ranolazine, nicora
Page 42 and 43: - Combinaties en werkzaamheid angor
Page 44 and 45: Anti-anginosa - ongewenste effecten
Page 50 and 51: Invasieve behandeling www.farmaka.b
Page 52 and 53: - Aanvullende medicatie bij PCI -
Page 54 and 55: www.farmaka.be Project Farmaka
Page 56 and 57: - Terminologie invasieve ingrepen -
Page 58 and 59: PTCA vs enkel medicatie 53.Borzak.
Page 60 and 61: - PTCA vs enkel medicatie - • Bej
Page 62 and 63: - CABG vs enkel medicatie - • ↓
Page 64: -Stents - Bedoeling stents en DES:
Page 67 and 68: - CABG vs PTCA - • CABG: meer CVA
Page 69 and 70: Onderhoudsbehandeling Globale CV pr
Page 71 and 72: Rookstop Gami P. Secondary preventi
Page 73 and 74: Mediterraan dieet 1.Gami P. Seconda
Page 75 and 76: Oefentherapie 77. Gami P. Secondary
Page 77 and 78: - Oefentherapie - • Vs “usual t
Page 79 and 80: - Stressmanagement - • Mogelijk
Page 81 and 82: - β-blokkers - Zie hoger www.farma
Page 83 and 84: Anti-aggregantia - ASA Gami P. Seco
Page 85 and 86: Consensusvergadering angor 2006. Di
Page 87 and 88: Anti-aggregantia - Ticlopidine en
Page 89: ACE-inhibitoren • Bij hoogrisicop
Page 93 and 94: -Statines - • ↓ mortaliteit en
Page 95 and 96: - Kernboodschappen - Patiënt met s
Page 97 and 98: - Symptomatische behandeling - •
show all

Presentatie - vzw farmaka asbl

Create successful ePaper yourself

Delete template?

Save as template?